Certa Dose -Award Winning Pediatric Dosing Device to Debut at Emergency Nurses Association 2016

    LOS ANGELES, CA, September 15, 2016 /24-7PressRelease/ -- Certa Dose, Inc. will introduce the Certa Dose Syringe Solution to the conference attendees at the ENA Emergency Nurses Association (ENA) Annual Conference 2016 on September 14-17, 2016. At least seven thousand children die each year from Medical Errors. Medication dosing errors are the #1 medical error in pediatric patients. Certa Dose was developed by an Emergency Department physician with the goal of reducing medical dosing errors in pediatrics. The patented, award winning device will be shown at Booth # 2006 in the Exhibit Hall.

"We couldn't be more excited to show the new solutions from Certa Dose at the largest emergency nursing conference. The ENA Annual Conference is one of the best opportunities to talk face-to-face with such an elite group", says Ms. Sarah Hanssen, President and CEO of Certa Dose, Inc. Dr. Caleb Hernandez, Certa Dose inventor will also be attending the conference and states, "We are anxious to share our clinical results indicating a reduction of critical errors from as much as 37% using today's standard of care to 0% using Certa Dose Color-Coded Syringes."

Attendees may stop by booth #2006 to be among the first to see the soon-to-be released, (pending FDA clearance), Certa Dose Solutions. This innovative system uses the universal pediatric nine color coded zones first introduced by Broselow-Luten, providing a simpler and more effective solution for pediatric dosing. Certa Dose Solutions provide confirmation through use of color matching. Simply measure and match.

Certa Dose, Inc. is a privately owned Delaware C Corporation with operations in Denver, Colorado and Indianapolis, Indiana. Certa Dose was founded in 2013 by Dr. Caleb Hernandez to solve the issue of medical dosing errors in pediatrics.

Currently we are working with regulatory authorities to obtain the required clearances to bring the first Certa Dose products to market.

# # #